-
Je něco špatně v tomto záznamu ?
Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury
C. Reichetzeder, K. von Websky, O. Tsuprykov, A. Mohagheghi Samarin, LG. Falke, SE. Dwi Putra, AA. Hasan, V. Antonenko, C. Curato, J. Rippmann, T. Klein, B. Hocher,
Jazyk angličtina Země Velká Británie
Typ dokumentu srovnávací studie, časopisecké články
NLK
Free Medical Journals
od 1968 do Před 1 rokem
PubMed Central
od 1968 do 2020
Europe PubMed Central
od 1968 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2002-01-01 do Před 1 rokem
Wiley Free Content
od 1997 do Před 1 rokem
PubMed
28423178
DOI
10.1111/bph.13822
Knihovny.cz E-zdroje
- MeSH
- adamantan aplikace a dávkování analogy a deriváty chemie farmakologie MeSH
- dipeptidylpeptidasa 4 metabolismus MeSH
- inhibitory dipeptidylpeptidasy 4 aplikace a dávkování chemie farmakologie MeSH
- krysa rodu rattus MeSH
- ledviny účinky léků metabolismus patologie MeSH
- linagliptin aplikace a dávkování chemie farmakologie MeSH
- molekulární struktura MeSH
- nitrily aplikace a dávkování chemie farmakologie MeSH
- potkani Wistar MeSH
- pyrrolidiny aplikace a dávkování chemie farmakologie MeSH
- reperfuzní poškození farmakoterapie metabolismus patologie MeSH
- sitagliptin fosfát aplikace a dávkování chemie farmakologie MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- vztahy mezi strukturou a aktivitou MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- srovnávací studie MeSH
BACKGROUND AND PURPOSE: Results regarding protective effects of dipeptidyl peptidase 4 (DPP4) inhibitors in renal ischaemia-reperfusion injury (IRI) are conflicting. Here we have compared structurally unrelated DPP4 inhibitors in a model of renal IRI. EXPERIMENTAL APPROACH: IRI was induced in uninephrectomized male rats by renal artery clamping for 30 min. The sham group was uninephrectomized but not subjected to IRI. DPP4 inhibitors or vehicle were given p.o. once daily on three consecutive days prior to IRI: linagliptin (1.5 mg·kg-1·day-1), vildagliptin (8 mg·kg-1·day-1) and sitagliptin (30 mg·kg-1·day-1). An additional group received sitagliptin until study end (before IRI: 30 mg·kg-1·day-1; after IRI: 15 mg·kg-1·day-1). KEY RESULTS: Plasma-active glucagon-like peptide type 1 (GLP-1) increased threefold to fourfold in all DPP4 inhibitor groups 24 h after IRI. Plasma cystatin C, a marker of GFR, peaked 48 h after IRI. Compared with the placebo group, DPP4 inhibition did not reduce increased plasma cystatin C levels. DPP4 inhibitors ameliorated histopathologically assessed tubular damage with varying degrees of drug-specific efficacies. Renal osteopontin expression was uniformly reduced by all DPP4 inhibitors. IRI-related increased renal cytokine expression was not decreased by DPP4 inhibition. Renal DPP4 activity at study end was significantly inhibited in the linagliptin group, but only numerically reduced in the prolonged/dose-adjusted sitagliptin group. Active GLP-1 plasma levels at study end were increased only in the prolonged/dose-adjusted sitagliptin treatment group. CONCLUSIONS AND IMPLICATIONS: In rats with renal IRI, DPP4 inhibition did not alter plasma cystatin C, a marker of glomerular function, but may protect against tubular damage.
Cardio Metabolic Diseases Boehringer Ingelheim Pharma GmbH and Co KG Biberach Germany
Center for Cardiovascular Research Charité Universitätsmedizin Berlin Berlin Germany
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18010665
- 003
- CZ-PrNML
- 005
- 20180418122514.0
- 007
- ta
- 008
- 180404s2017 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/bph.13822 $2 doi
- 035 __
- $a (PubMed)28423178
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Reichetzeder, Christoph $u Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany. Center for Cardiovascular Research, Charité - Universitätsmedizin Berlin, Berlin, Germany.
- 245 10
- $a Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury / $c C. Reichetzeder, K. von Websky, O. Tsuprykov, A. Mohagheghi Samarin, LG. Falke, SE. Dwi Putra, AA. Hasan, V. Antonenko, C. Curato, J. Rippmann, T. Klein, B. Hocher,
- 520 9_
- $a BACKGROUND AND PURPOSE: Results regarding protective effects of dipeptidyl peptidase 4 (DPP4) inhibitors in renal ischaemia-reperfusion injury (IRI) are conflicting. Here we have compared structurally unrelated DPP4 inhibitors in a model of renal IRI. EXPERIMENTAL APPROACH: IRI was induced in uninephrectomized male rats by renal artery clamping for 30 min. The sham group was uninephrectomized but not subjected to IRI. DPP4 inhibitors or vehicle were given p.o. once daily on three consecutive days prior to IRI: linagliptin (1.5 mg·kg-1·day-1), vildagliptin (8 mg·kg-1·day-1) and sitagliptin (30 mg·kg-1·day-1). An additional group received sitagliptin until study end (before IRI: 30 mg·kg-1·day-1; after IRI: 15 mg·kg-1·day-1). KEY RESULTS: Plasma-active glucagon-like peptide type 1 (GLP-1) increased threefold to fourfold in all DPP4 inhibitor groups 24 h after IRI. Plasma cystatin C, a marker of GFR, peaked 48 h after IRI. Compared with the placebo group, DPP4 inhibition did not reduce increased plasma cystatin C levels. DPP4 inhibitors ameliorated histopathologically assessed tubular damage with varying degrees of drug-specific efficacies. Renal osteopontin expression was uniformly reduced by all DPP4 inhibitors. IRI-related increased renal cytokine expression was not decreased by DPP4 inhibition. Renal DPP4 activity at study end was significantly inhibited in the linagliptin group, but only numerically reduced in the prolonged/dose-adjusted sitagliptin group. Active GLP-1 plasma levels at study end were increased only in the prolonged/dose-adjusted sitagliptin treatment group. CONCLUSIONS AND IMPLICATIONS: In rats with renal IRI, DPP4 inhibition did not alter plasma cystatin C, a marker of glomerular function, but may protect against tubular damage.
- 650 _2
- $a adamantan $x aplikace a dávkování $x analogy a deriváty $x chemie $x farmakologie $7 D000218
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a dipeptidylpeptidasa 4 $x metabolismus $7 D018819
- 650 _2
- $a inhibitory dipeptidylpeptidasy 4 $x aplikace a dávkování $x chemie $x farmakologie $7 D054873
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a ledviny $x účinky léků $x metabolismus $x patologie $7 D007668
- 650 _2
- $a linagliptin $x aplikace a dávkování $x chemie $x farmakologie $7 D000069476
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a nitrily $x aplikace a dávkování $x chemie $x farmakologie $7 D009570
- 650 _2
- $a pyrrolidiny $x aplikace a dávkování $x chemie $x farmakologie $7 D011759
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a reperfuzní poškození $x farmakoterapie $x metabolismus $x patologie $7 D015427
- 650 _2
- $a sitagliptin fosfát $x aplikace a dávkování $x chemie $x farmakologie $7 D000068900
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a von Websky, Karoline $u Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany. Center for Cardiovascular Research, Charité - Universitätsmedizin Berlin, Berlin, Germany.
- 700 1_
- $a Tsuprykov, Oleg $u Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany. Center for Cardiovascular Research, Charité - Universitätsmedizin Berlin, Berlin, Germany. Institut für Laboratoriumsmedizin, Berlin, Germany.
- 700 1_
- $a Mohagheghi Samarin, Azadeh $u Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany. Institute of Aquaculture, University of South Bohemia, České Budějovice, Czech Republic.
- 700 1_
- $a Falke, Luise Gabriele $u Center for Cardiovascular Research, Charité - Universitätsmedizin Berlin, Berlin, Germany.
- 700 1_
- $a Dwi Putra, Sulistyo Emantoko $u Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany. Faculty of Biotechnology, University of Surabaya, Surabaya, Indonesia.
- 700 1_
- $a Hasan, Ahmed Abdallah $u Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany. Department of Biochemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.
- 700 1_
- $a Antonenko, Viktoriia $u Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany. Center for Cardiovascular Research, Charité - Universitätsmedizin Berlin, Berlin, Germany.
- 700 1_
- $a Curato, Caterina $u German Rheumatism Research Center (DRFZ), Berlin, Germany. Cluster of Excellence NeuroCure, Charité - Universitätsmedizin Berlin, Berlin, Germany.
- 700 1_
- $a Rippmann, Jörg $u Cardio Metabolic Diseases, Boehringer-Ingelheim Pharma GmbH&Co KG, Biberach, Germany.
- 700 1_
- $a Klein, Thomas $u Cardio Metabolic Diseases, Boehringer-Ingelheim Pharma GmbH&Co KG, Biberach, Germany.
- 700 1_
- $a Hocher, Berthold $u Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany. Institut für Laboratoriumsmedizin, Berlin, Germany. Department of Basic Medicine, Medical College of Hunan Normal University, Changsha, China.
- 773 0_
- $w MED00009383 $t British journal of pharmacology $x 1476-5381 $g Roč. 174, č. 14 (2017), s. 2273-2286
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28423178 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180404 $b ABA008
- 991 __
- $a 20180418122614 $b ABA008
- 999 __
- $a ok $b bmc $g 1288150 $s 1007477
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 174 $c 14 $d 2273-2286 $e 20170607 $i 1476-5381 $m British journal of pharmacology $n Br J Pharmacol $x MED00009383
- LZP __
- $a Pubmed-20180404